Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ROCKET PHARMACEUTICALS, INC. Director's Dealing 2023

Aug 30, 2023

33148_dirs_2023-08-30_fb94d405-9bf7-41d7-a853-961c88babe7b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2023-08-28

Reporting Person: RTW INVESTMENTS, LP (Director, 10% Owner, See Remarks)
Reporting Person: WONG RODERICK (Director, 10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-08-28 Common Stock, $0.01 par value ("Common Stock") J 500000 $22.05 Acquired 18657605 Indirect
2023-08-28 Common Stock J 500000 $15.87 Disposed 18157605 Indirect
2023-08-28 Common Stock J 500000 $22.05 Disposed 17657605 Indirect
2023-08-28 Common Stock J 500000 $15.87 Acquired 18157605 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-08-28 Equity Swap (obligation to buy) $22.05 J 1 Disposed 2023-08-28 Common Stock (500000) Indirect
2023-08-28 Equity Swap (obligation to sell) $22.05 J 1 Disposed 2023-08-28 Common Stock (500000) Indirect

Footnotes

F1: This Form 4 is being filed in connection with the equity swap transactions described below. After the transactions reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change.

F2: On August 28, 2023, the equity swap entered into by RTW Innovation Master Fund, Ltd. previously reported on the Form 4 filed by the Reporting Persons on August 29, 2018 (the "2018 Form 4"), expired and settled in accordance with its terms. The 2018 Form 4 reported the entry by RTW Innovation Master Fund, Ltd. into an equity swap (obligation to sell); RTW Innovation Master Fund, Ltd. in fact entered into an equity swap (obligation to buy).

F3: On August 28, 2023, the equity swap entered into by RTW Master Fund, Ltd. previously reported on the 2018 Form 4, expired and settled in accordance with its terms. The 2018 Form 4 reported the entry by RTW Master Fund, Ltd. into an equity swap (obligation to buy); RTW Master Fund, Ltd. in fact entered into an equity swap (obligation to sell).

F4: This Form 4 is being filed by each of (i) RTW Investments, LP (the "Adviser") with respect to the securities held by certain investment funds managed by the Adviser (the "RTW Funds") and (ii) Roderick Wong, M.D. ("Dr. Wong"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors.